Study shows Xultophy boosts glycaemic targets

By Editor
21st September 2016
Hypoglycaemia, Latest news Pharmaceutical Research

Adults with type 2 diabetes treated with Xultophy® (insulin degludec/liraglutide) are up to 4.5 times more likely to achieve glycaemic targets without hypoglycaemia and weight gain, research has suggested.

The Novo Nordisk trial compared two groups of type 2 diabetes patients uncontrolled on insulin glargine U100, treated with either insulin degludec/liraglutide or up-titrated insulin glargine U100.

In the UK, 90 per cent of adults who have type 2 diabetes are either overweight or obese, which is why achieve good glycaemic control without weight is so important.

Hypoglycaemia and weight gain are two of the most common complications of insulin treatments.

‘Long-term health’

Fear of hypoglycaemia is also a commonly reported problem, because it can impact quality of life, affecting sleep patterns, relationships and the ability to work.

Adie Viljoen, consultant chemical pathologist and lipidologist at East and North Hertfordshire NHS Trust and investigator for the DUAL I study, said: “The results from the DUAL V analysis are encouraging.

“Hypoglycaemia and weight gain are two of the most common complications of insulin treatments. The ability to reach glycaemic targets with insulin degludec/liraglutide, while reducing the risk of unwanted side effects, such as hypoglycaemia, has the potential to improve patients’ quality of life and long-term health.”

Results of the DUAL V post-hoc analysis showed:

  • Adults treated with insulin degludec/liraglutide were 4.55 times more likely to
    achieve fasting plasma glucose (FPG) targets ( hypoglycaemia and weight gain* versus up-titration with insulin glargine U100
    (41.4 per cent vs 14.3 per cent, p<0.0001)
  • Significantly more adults treated with insulin degludec/liraglutide achieved a HbA1c
    target of <7 per cent with no hypoglycaemia and no weight gain across baseline HbA1c
    groups versus up-titration with insulin glargine U100
  • FPG and HbA1c were already significantly reduced at weeks 4, 8 and 12, showing
    better glycaemic control shortly after transferring to insulin degludec/liraglutide
    versus up-titration with insulin glargine U100

Xultophy® is a once-daily single injection co-formulation of basal insulin analogue (insulin degludec) and GLP-1 agonist (liraglutide).

The maximum dose of insulin degludec/liraglutide is 50 dose steps (equivalent to 50 units of insulin degludec and 1.8 mg of liraglutide).

This treatment has been investigated in six trials in the DUAL clinical trial programme, encompassing more than 3850 people with type 2 diabetes. Phase 3b trials are still ongoing.

Comments (0)

Register an account or login to comment